Skip to content

Stroke Prevention in Atrial Fibrillation

Atrial fibrillation (AF) can promote clot formation in the heart and embolic stroke. Not everyone with AF has the same risk, so anticoagulation decisions use clinical risk and bleeding assessment rather than rhythm symptoms alone.

Key takeaways

  • AF can be intermittent or symptom-free; stroke risk relates to factors such as age, previous stroke and other cardiovascular disease.
  • Anticoagulants reduce clot risk but increase bleeding risk, so kidney function, interactions, adherence and procedures matter.
  • Antiplatelet medicines are not equivalent substitutes for anticoagulation when AF-related stroke prevention is indicated.

Catalogue matches do not diagnose AF, calculate personal risk or show that an anticoagulant and dose are safe.

How is the decision made?

Clinicians confirm AF and assess stroke and bleeding factors together. Falls, frailty or previous bleeding require individual discussion rather than automatic treatment or automatic exclusion. The plan is reviewed as health changes.

What affects anticoagulant choice?

Rivaroxaban is one direct oral anticoagulant. Kidney and liver function, age, weight, valve disease, pregnancy, interacting medicines and adherence affect selection and dose. Missing doses or stopping for a procedure requires prescriber guidance; see heart and blood pressure.

When to seek urgent care

Call emergency services for sudden face droop, arm weakness, speech or vision change, loss of balance or severe headache. Heavy bleeding, vomiting blood, black stools, collapse or head injury while anticoagulated also needs urgent care.